# EU Melanoma Therapeutics Market

> Europe Melanoma Therapeutics Market Research Report Information By Product (Chemotherapy, Immunotherapy, Targeted Therapy, and Radiation Therapy), By Drug Type (Branded Drugs, and Generic Drugs) By Region (Germany, France, UK, Italy, Spain, Sweden, Denmark, Luxembourg, Norway, Austria, and Rest of Europe)–and Europe Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 16.8%
- **2024:** $ 1.25 Billion
- **2025:** $ 1.46 Billion
- **2035:** $ 6.9 Billion
- **Key Players:** Bristol Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Amgen (US), Sanofi (FR), Eli Lilly and Company (US), Regeneron Pharmaceuticals (US), GSK (GB)

**Report ID:** MRFR/HC/20194-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/eu-melanoma-therapeutics-market-21792

---

## Market Summary

## **Europe Melanoma Therapeutics Market Overview**

Europe Melanoma Therapeutics Market Size was valued at USD 0.92 Billion in 2022. The Melanoma Therapeutics market industry is projected to grow from USD 1.07 Billion in 2023 to USD 3.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.80% during the forecast period (2023 - 2032). The growing need for radiation treatment is one of the major market drivers driving the Melanoma Therapeutics market in Europe. The market saw partnerships and collaborations, as well as acquisitions, as inorganic growth tactics. The market participants' consumer base and business have grown as a result of these activities.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

December 27th, 2023, Bristol Myers Squibb’s Opdivo+Yervoy combination consisting of nivolumab and relatlimab won approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) United Kingdom for advanced melanoma. Project Orbis authorized Opdualag as well; it acts together with Canada’s Health Canada, Australia’s Medicines Goods Administration (TGA), Singapore’s Health Sciences Authority (HSA), Swissmedic, Anvisa Brazil and Israel Ministry of Health partners coordinated by US Food and Drug Administration (FDA). The aim is to speed up safe and effective drug development through concurrent submission reviewing plans among countries.

It also helps bring products to other countries where sponsors are willing to accept foreign data as support for their applications earlier.

Moderna CEO Stephane Bancel told AFP on Tuesday that his firm's experimental vaccine against melanoma could be available within two years after clinical trials are concluded if all goes well, conducting a major war against the deadliest type of skin cancer, which is not easy or simple. Globally, an estimated three hundred twenty-five thousand melanoma cases occurred there alone in the year 2020, while this disease alone claimed about fifty-seven thousand lives.

**In September 2023**, the FDA pushed back its Prescription Drug User Fee Act (PDUFA) date for Iovance Biotherapeutics’ life in advanced melanoma patients from November 25th, 2023, to February 2024. The agency said it needed more time because of limited resources. The biologics license application is still under priority review, and no major review issues are indicated by the FDA. There will be no advisory committee meeting convened as part of this process either. Furthermore, all pre-approval inspections of clinical sites, as well as manufacturing and testing facilities, have been completed.

**In October 2022**, Quest Diagnostics Incorporated announced that it had joined forces with Decode Health to obtain biomarker-based information that will cut short the time and cost of developing new tests and drug targets for different kinds of cancer. This would also advance the company’s R&D innovation in Europe as well as its market expansion.

**In May 2022**, Myriad Genetics, Inc. was reported to have broadened its strategic alliance with Intermountain Precision Genomics, a service of Intermountain Healthcare, by adding a new liquid biopsy therapy selection test into its burgeoning oncology portfolio. We are seeing greater room for liquid biopsy in this cancer diagnosis.

## **Melanoma Therapeutics Market Trends**

Melanoma is the name for the most deadly type of skin cancer, and it starts in the melanocyte cells, which are in charge of making melanin. Melanoma can also occur in the eyes and, very infrequently, in other body parts like the throat and nose. Because more people are being treated with radiation as adjuvant therapy after surgery and the number of instances of advanced melanoma is rising, radiation therapy is expected to expand steadily in Europe during the projection period. One common initial course of treatment is radiation therapy.

Only stage 4 patients who are not responsive to surgery are given it. Since melanoma, skin allergies, and other skin malignancies are more common in developing nations like Europe, there is a chance for many pharmaceutical companies to increase their market share in these areas.

Furthermore, putting a lot of focus and money into creating extremely effective treatment choices will probably have a big effect on market expansion in the European region. The number of approvals by regulators has had a significant impact on market growth, and treatment recommendations are contingent upon a number of factors. Among the medications that the FDA approved in 2021 for the treatment of cancer were Binimetinib, Braftovi, Aldesleukin, Cobimetinib Fumarate, Dabrafenib Mesylate, and Cotellic. The market's expansion in the next years will be supported by the importance of major key players introducing various novel medications and treatment methods.

However, sometimes, especially in developing nations like Europe, no medication is available to treat the wide variety of malignancies that might occur.

## **Melanoma Therapeutics Market Segment Insights**

### **Melanoma Therapeutics Product Insights**

The Europe Melanoma Therapeutics market segmentation, based on Product, includes Chemotherapy, [Immunotherapy](../../../reports/immunotherapy-drugs-market-7399), Targeted Therapy, and Radiation Therapy. The market for melanoma therapies is dominated by immunotherapy because of its exceptional efficacy and generally good safety record. It has transformed the way melanoma is treated by combating cancer cells with the immune system. Pembrolizumab and Nivolumab, two immune checkpoint inhibitors, have demonstrated remarkable response rates that have increased patient survival.

### **Melanoma Therapeutics Drug Type Insights**

The Europe Melanoma Therapeutics market segmentation, based on Drug Type, includes Branded Drugs and Generic Drugs. The melanoma therapeutics market is dominated by the branded drugs segment, largely because of strong clinical trial pipelines, substantial investments in research and development, and effective marketing strategies employed by pharmaceutical companies. Branded medications frequently give a better degree of safety and efficacy, fostering patient and healthcare provider trust.

**Figure 1: Europe Melanoma Therapeutics Market, by Drug Type, 2022 & 2032 (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Melanoma Therapeutics Country Insights**

Germany is the largest share-holding country in Europe melanoma therapeutics market in the European region. The need for efficacious treatments is exacerbated by the prevalence of melanoma in Germany. Research, development, and adoption of cutting-edge treatments may be influenced by a large number of instances. Promising outcomes have been observed in the treatment of melanoma using immunotherapy. Melanoma therapies are growing as a result of ongoing developments in immune checkpoint inhibitors and other immunotherapeutic strategies. Germany offers access to cutting-edge and novel therapies because of its sophisticated healthcare system.

The newest and most potent melanoma treatments are sought after by patients and medical professionals.

**Figure 2: Europe Melanoma Therapeutics Market Share By Region 2022 & 2032  (USD Billion)**

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Melanoma Therapeutics Key Market Players & Competitive Insights**

Leading market players are investing a substantial amount of money in R&D to grow their product lines, which will contribute to the further expansion of the Melanoma Therapeutics market. In addition, market players are engaging in a range of calculated initiatives to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure an increasingly cutthroat and dynamic market, the Melanoma Therapeutics industry must provide reasonably priced goods.

Major players in the Melanoma Therapeutics market are engaging in research and development activities in an effort to boost market demand, including Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. ( France), Bayer AG (Germany), Lilly (U.S.), and Merck & Co., Inc. (U.S.), among others.

**Key Companies in the Melanoma Therapeutics Market Include**

**Melanoma Therapeutics Industry Developments**

**January 2022:**Pfizer Inc. received approval for CIBINQO (abrocitinib) from the US Food and Drug Administration (FDA). This once-daily oral drug is part of the Janus kinase 1 (JAK1) inhibitor class and is used for individuals with moderate-to-severe atopic dermatitis (AD) that is refractory.

**January 2022:**FDA approved Immunocore's KIMMTRAK (tebentafusp-tebn). This drug is intended to treat metastatic or incurable uveal melanoma, providing a potentially effective treatment alternative in the battle against this difficult malignancy**.**

**August 2022:**Japan approved Tagrisso, an AstraZeneca product, as an adjuvant treatment for individuals with epidermal growth**.**

## **Melanoma Therapeutics Market Segmentation**

### **Melanoma Therapeutics Product Outlook**

### **Melanoma Therapeutics Drug Type Outlook**

### **Melanoma Therapeutics Regional Outlook**

## Market Drivers

### Increasing Incidence of Melanoma

The rising incidence of melanoma across Europe is a pivotal driver for the Europe Melanoma Therapeutics Market. Recent statistics indicate that melanoma cases have surged, with an estimated 200,000 new cases reported annually in Europe. This alarming trend necessitates the development and availability of effective therapeutic options. As awareness of skin cancer increases, more individuals are seeking early diagnosis and treatment, thereby propelling market growth. The heightened focus on melanoma prevention and treatment strategies is likely to stimulate research and development efforts, leading to innovative therapies. Consequently, the growing patient population is expected to drive demand for advanced melanoma therapeutics, thereby shaping the landscape of the Europe Melanoma Therapeutics Market.

### Advancements in Targeted Therapies

The emergence of targeted therapies represents a transformative shift in the Europe Melanoma Therapeutics Market. These therapies, designed to specifically target cancer cells while sparing healthy tissue, have shown promising results in clinical trials. For instance, BRAF and [MEK inhibitors](https://www.marketresearchfuture.com/reports/mek-inhibitors-market-32414) have gained traction, demonstrating improved survival rates among patients with specific genetic mutations. The market for targeted therapies is projected to expand significantly, with estimates suggesting a compound annual growth rate of over 15% in the coming years. This growth is driven by ongoing research and the increasing number of approved targeted agents, which are likely to enhance treatment options for melanoma patients. As a result, the integration of targeted therapies into clinical practice is expected to reshape treatment paradigms within the Europe Melanoma Therapeutics Market.

### Growing Investment in Cancer Research

The surge in investment for cancer research is a crucial driver for the Europe Melanoma Therapeutics Market. Governments and private organizations are increasingly allocating funds to support innovative research initiatives aimed at understanding melanoma biology and developing novel therapies. In 2025, it is estimated that research funding for melanoma will exceed 500 million euros across Europe, reflecting a commitment to combating this aggressive form of skin cancer. This influx of capital is likely to facilitate collaborations between academic institutions and pharmaceutical companies, fostering the development of cutting-edge treatments. As a result, the enhanced research landscape is expected to yield breakthroughs in melanoma therapeutics, ultimately benefiting patients and driving market growth.

### Rising Awareness and Education Campaigns

The increasing awareness of melanoma and skin cancer prevention is a vital driver for the Europe Melanoma Therapeutics Market. Public health campaigns aimed at educating individuals about the risks associated with UV exposure and the importance of early detection are gaining momentum. These initiatives are likely to lead to higher rates of skin examinations and earlier diagnoses, which can significantly impact treatment outcomes. As awareness grows, more patients are likely to seek therapeutic options, thereby driving market demand. Furthermore, educational programs targeting healthcare professionals are expected to enhance the quality of care provided to melanoma patients. This heightened awareness and education are anticipated to contribute positively to the growth trajectory of the Europe Melanoma Therapeutics Market.

### Regulatory Support for Innovative Therapies

Regulatory bodies in Europe are increasingly supportive of innovative therapies, which serves as a significant driver for the Europe Melanoma Therapeutics Market. Initiatives such as the European Medicines Agency's (EMA) accelerated approval pathways are designed to expedite the review process for promising new treatments. This regulatory environment encourages pharmaceutical companies to invest in the development of novel melanoma therapies, as they can bring products to market more swiftly. The potential for faster access to innovative treatments is likely to enhance patient outcomes and satisfaction, thereby increasing the overall demand for melanoma therapeutics. Consequently, the supportive regulatory framework is expected to play a vital role in shaping the future of the Europe Melanoma Therapeutics Market.

## Future Outlook

The Europe Melanoma Therapeutics Market is projected to grow at a 16.8% CAGR from 2025 to 2035, driven by advancements in immunotherapy, increasing incidence rates, and enhanced diagnostic techniques.

**New opportunities:**

- Development of personalized medicine platforms for targeted therapies. Expansion of telehealth services for remote patient monitoring. Investment in AI-driven drug discovery to expedite therapeutic development.

By 2035, the market is expected to be robust, driven by innovation and increased patient access.

## Segment Insights

### By Product: Immunotherapy (Largest) vs. Targeted Therapy (Fastest-Growing)

In the European melanoma therapeutics market, the product segment showcases a competitive landscape among [chemotherapy](https://www.marketresearchfuture.com/reports/chemotherapy-market-5791), [immunotherapy](https://www.marketresearchfuture.com/reports/immunotherapy-drugs-market-7399), targeted therapy, and radiation therapy. Immunotherapy holds the largest market share due to its effectiveness and acceptance by healthcare providers, capitalizing on innovative treatments like checkpoint inhibitors and personalized medicine. In contrast, targeted therapy is rapidly gaining traction as more patients seek tailored approaches to their treatment plans, reflecting an increasing demand for precision medicine centric solutions.

Therapeutics: Immunotherapy (Dominant) vs. Targeted Therapy (Emerging)

Immunotherapy is recognized as the dominant player in the Europe melanoma therapeutics market, with its roots deeply embedded in groundbreaking advancements that have provided effective treatment avenues for patients. This approach focuses on harnessing the body’s immune system to fight melanoma, often resulting in prolonged survival rates. Meanwhile, targeted therapy is emerging swiftly, distinguished by its ability to selectively target cancer cells while sparing healthy tissue. This therapy aligns well with the growing trend towards personalization in treatment options, catering to the unique genetic makeup of tumors, thus attracting attention from both oncologists and patients alike.

### By Drug Type: Branded Drugs (Largest) vs. Generic Drugs (Fastest-Growing)

In the Europe Melanoma Therapeutics Market, Branded Drugs hold the dominant market share, being widely recognized for their efficacy and safety profiles. These drugs are primarily backed by extensive clinical evidence and robust marketing strategies, which fortify their position in the therapeutic landscape. Conversely, Generic Drugs, while trailing in market share, are steadily capturing attention due to their cost-effectiveness and increasing acceptance among healthcare providers and patients.

Branded Drugs (Dominant) vs. Generic Drugs (Emerging)

Branded Drugs constitute the mainstay of the melanoma therapeutics segment, offering established treatments with significant clinical validation. Their brands are often synonymous with quality, leading to a strong consumer trust and loyalty. In contrast, Generic Drugs represent an emerging segment that is gaining traction due to their affordability and improved accessibility. As healthcare systems progressively emphasize cost containment, the appeal of Generic Drugs increases, creating a competitive push that challenges the established dominance of Branded Drugs. This dynamic signifies a transformative period in the melanoma therapeutics market.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

The North American melanoma therapeutics market is driven by advanced research, high healthcare expenditure, and a growing prevalence of melanoma. The U.S. holds the largest market share at approximately 70%, followed by Canada at around 15%. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, enhancing market growth. Increasing awareness and early detection initiatives further boost demand for effective treatments. Key players such as Bristol Myers Squibb, Merck & Co, and Amgen dominate the competitive landscape, leveraging their strong R&D capabilities. The presence of numerous clinical trials and collaborations with academic institutions fosters innovation. The market is characterized by a focus on immunotherapy and targeted therapies, with companies continuously striving to improve patient outcomes and expand their product portfolios.

### Europe : Expanding Therapeutic Options

The European melanoma therapeutics market is experiencing significant growth, driven by increasing melanoma incidence and advancements in treatment options. Germany and France are the largest markets, holding approximately 30% and 20% market shares, respectively. Regulatory frameworks, such as the European Medicines Agency's guidelines, facilitate the introduction of novel therapies, enhancing patient access to effective treatments. The rising focus on personalized medicine is also a key growth driver. Leading countries like the UK, Italy, and Spain contribute to the competitive landscape, with major players such as Roche, Novartis, and Sanofi actively involved. The market is characterized by a mix of established therapies and emerging treatments, with a strong emphasis on immunotherapy. Collaborative efforts between pharmaceutical companies and research institutions are fostering innovation, ensuring a steady pipeline of new therapies to meet the growing demand.

### Asia-Pacific : Emerging Market Potential

The Asia-Pacific melanoma therapeutics market is on the rise, driven by increasing awareness of skin cancer and improving healthcare infrastructure. Countries like Australia and Japan are leading the market, with Australia holding approximately 25% of the share due to its high melanoma incidence rates. The region is witnessing a shift towards advanced treatment options, supported by regulatory bodies that are streamlining approval processes for new therapies. The competitive landscape features both local and international players, with companies like GSK and Eli Lilly making significant inroads. The focus on research and development is growing, with an emphasis on targeted therapies and immunotherapies. As healthcare access improves, the demand for effective melanoma treatments is expected to rise, presenting substantial growth opportunities for stakeholders in the region.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa melanoma therapeutics market is still in its nascent stages, with significant growth potential driven by increasing awareness and healthcare improvements. Countries like South Africa and the UAE are leading the market, holding approximately 20% and 15% shares, respectively. The region faces challenges such as limited access to advanced therapies, but ongoing investments in healthcare infrastructure are expected to enhance treatment availability and patient outcomes. The competitive landscape is evolving, with both multinational and local companies exploring opportunities in the melanoma therapeutics space. Key players are beginning to establish a presence, focusing on education and awareness campaigns to drive demand. As regulatory frameworks improve, the market is poised for growth, with a focus on innovative treatment options to address the rising incidence of melanoma.

## Competitive Benchmarking

Leading market players are investing a substantial amount of money in R&D to grow their product lines, which will contribute to the further expansion of the Melanoma Therapeutics market. In addition, market players are engaging in a range of calculated initiatives to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure an increasingly cutthroat and dynamic market, the Melanoma Therapeutics industry must provide reasonably priced goods. Major players in the Melanoma Therapeutics market are engaging in research and development activities in an effort to boost market demand, including Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. ( France), Bayer AG (Germany), Lilly (U.S.), and Merck & Co., Inc. (U.S.), among others.

## Recent News & Developments

**January 2022:**Pfizer Inc. received approval for CIBINQO (abrocitinib) from the US Food and Drug Administration (FDA). This once-daily oral drug is part of the Janus kinase 1 (JAK1) inhibitor class and is used for individuals with moderate-to-severe atopic dermatitis (AD) that is refractory.

**January 2022:**FDA approved Immunocore's KIMMTRAK (tebentafusp-tebn). This drug is intended to treat metastatic or incurable uveal melanoma, providing a potentially effective treatment alternative in the battle against this difficult malignancy**.**

**August 2022:**Japan approved Tagrisso, an AstraZeneca product, as an adjuvant treatment for individuals with epidermal growth**.**

## Report Scope

| MARKET SIZE 2024 | 1.25(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.46(USD Billion) |
| MARKET SIZE 2035 | 6.898(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol Myers Squibb (US), Merck & Co (US), Roche (CH), Novartis (CH), Amgen (US), Sanofi (FR), Eli Lilly and Company (US), Regeneron Pharmaceuticals (US), GSK (GB) |
| Segments Covered | Product, Drug Type, Region |
| Key Market Opportunities | Emergence of novel immunotherapies and targeted therapies enhances treatment options in the Europe Melanoma Therapeutics Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Europe Melanoma Therapeutics Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Europe Melanoma Therapeutics Market?**
A: The market valuation was 1.25 USD Billion in 2024.

**Q: What is the projected market size for the Europe Melanoma Therapeutics Market by 2035?**
A: The projected valuation for 2035 is 6.898 USD Billion.

**Q: What is the expected CAGR for the Europe Melanoma Therapeutics Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 16.8%.

**Q: Which product segments are included in the Europe Melanoma Therapeutics Market?**
A: The product segments include Chemotherapy, Immunotherapy, Targeted Therapy, and Radiation Therapy.

**Q: What were the revenue figures for Immunotherapy in 2024?**
A: Immunotherapy generated revenues of 0.5 USD Billion in 2024.

**Q: How do branded drugs compare to generic drugs in the Europe Melanoma Therapeutics Market?**
A: Branded drugs accounted for 0.75 USD Billion, while generic drugs accounted for 0.5 USD Billion in 2024.

**Q: Who are the key players in the Europe Melanoma Therapeutics Market?**
A: Key players include Bristol Myers Squibb, Merck & Co, Roche, Novartis, Amgen, Sanofi, Eli Lilly and Company, Regeneron Pharmaceuticals, and GSK.

**Q: What is the revenue range for Targeted Therapy in the Europe Melanoma Therapeutics Market?**
A: Targeted Therapy is projected to range from 0.3 to 1.5 USD Billion.

**Q: What is the expected growth trend for Radiation Therapy in the coming years?**
A: Radiation Therapy is expected to grow from 0.2 USD Billion to 1.0 USD Billion by 2035.

**Q: How does the market's growth potential impact investment opportunities?**
A: The robust growth potential, indicated by a projected CAGR of 16.8%, suggests lucrative investment opportunities in the market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/eu-melanoma-therapeutics-market-21792*